The aberrant expression of ASPM, AURKA, BUB1, BUB1B, MELK, NUF2, and PBK resulted in a poorer survival rate of GBM patients in the high-risk group with a survival rate of fewer than two years. Here, BUB1B is linked to glioblastoma.